Results 211 to 220 of about 1,097,093 (360)
CircSMEK1 Suppresses HCC via the hnRNPK‐IGF2‐AKT Axis: A Diagnostic Biomarker and Therapeutic Target
CircSMEK1 is downregulated in MASH/HCC and predicts poor prognosis. It suppresses tumor progression by promoting hnRNPK ubiquitination and inhibiting the IGF2/PI3K/AKT axis, while its loss activates immunosuppressive cancer‐associated fibroblasts. Serum circSMEK1 serves as a non‐invasive diagnostic biomarker, and its restoration potently inhibits HCC ...
Peilan Guo +15 more
wiley +1 more source
Histologic Findings of Antibody-Mediated Rejection in ABO Blood-Group-Incompatible Living-Donor Kidney Transplantation [PDF]
Mary E. Fidler +12 more
openalex +1 more source
Thrombotic microangiopathy and rejection in blood group incompatible renal transplantation
openaire +3 more sources
The study has developed the first clinically validated hybrid EEG‐fNIRS brain‐computer interface fusion framework that systematically overcomes cross‐subject generalization barriers through a novel Wasserstein metric‐driven neural template selection mechanism.
Danyang Chen +18 more
wiley +1 more source
CRB‐2131, as a novel Nox inhibitor, suppresses brain oxidation, tauopathy, and neuro‐inflammation, thereby preventing death of mature neurons and promoting regeneration of immature neurons. Ultimately, this fosters a resilient brain and protects cognition.
Jihyeon Lee +13 more
wiley +1 more source
tRF‐22 fosters an immunosuppressive and pro‐oncogenic tumor microenvironment in ESCC by stabilizing hnRNPAB against TRIM25‐mediated ubiquitination and enhancing TGFβ2 expression, which increases PMN‐MDSCs infiltration and suppresses CD8+ T cells. Targeting tRF‐22 or blocking TGFβ signalling improves anti‐PD1 response, offering a promising therapeutic ...
Ling Pan +10 more
wiley +1 more source
Pure Red Cell Aplasia After ABO-Incompatible Allogeneic Hematopoietic Stem Cell Transplantation Successfully Treated With Daratumumab: Report of Two Cases. [PDF]
Bertone EJ +6 more
europepmc +1 more source

